Dr Tan Sui Keat, Rumah Sakit Icon Cancer Centre

Kualifikasi

MD(UKM)
MRCP(UK)
Fellowship in Clinical Haematology (MOH)
Fellowship in Bone Marrow and Stem Cell Transplantation (Aust)
DipRCPath (Haematology)(UK)

Spesialisasi

Hematologi Klinis

Ketertarikan Spesial

Transplantasi sumsum tulang
Terapi seluler
Leukemia
Limfoma
Mieloma multipel

Afiliasi dan Keanggotaan

Member of Malaysian Society of Hematology since 2016
Member of Penang Thalassemia Society since 2016
Member of European Hematology Association from 2018-2019
Associate member of American Society of Hematology International Associate Member since 2021
Individual Life Member of European Society of Blood and Marrow Transplant (2023-2025)

Uji Klinis

COMMODORE (2018) – A Randomised, Open Label Phase 3 study assessing the safety and tolerability of the oral FLT3 inhibitor Gliteritinib versus salvage chemotherapy in relapsed or refractory AML – Co-investigator
EXPLORER 4 (2018) – A Randomised, Open Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylatic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors – Co-investigator
BELIEVE (2018) – A Phase 3, double blind, randomized, placebo-controlled, multicentre study to determine the efficacy and safety of luspatercept plus Best Supportive Care versus placebo plus BSC in adults who require regular red blood cell transfusion due to Beta Thalassemia – Co-investigator
VIALE –T (2020) – A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitdine after ASCT in subjects with AML – Co-investigator
VEDO-3035 (2020) – A Randomized, Double Blind, Placebo – controlled, Multicenter Study to evaluate the efficacy and safety of Vedolizumab in the prophylaxis of Intestinal acute GVHD in subjects undergoing alloSCT – Co-investigator
ASSURE (2020) – A Phase II dose escalation study of cyclophosphamide in hematopoietic stem cell transplantation in severe systemic sclerosis patient unfit for standard dose of cyclophosphamide – Co-investigator
IMARA (2021) — A Phase 2, Randomized, Double Blind, Placebo controlled study to evaluate the safety, tolerability, PK and PD of IMR-687 in adult subjects with B-Thalassemia – Co-investigator
BO42162 (2021) – A Phase III, Randomized, Open Label Active Controlled, Multicenter Study Evaluating the Efficacy and Safety of Crovalimab versus Eculizumab in adult and adolescent patients with PNH not previously treated with complement inhibitors – Co-investigator
CABL001J12301(2022) – A Phase III, multi-center, open-label, randomized study of oral asciminib versus investigator selected TKI in patients with newly diagnosed CML in CP – Co-investigator
CABL001A2302(2022) – A Phase 3b, multi-center, open-label, treatment optimization study of oral asciminib in patients with CML in CP previously treated with 2 or more TKI – Co-investigator
MANIFEST II (2023) – A Phase 3, Randomized, Double – Blind, Active Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs Placebo and Ruxolitinib in JAKi Treatment Naïve MF Patients – Principal Investigator
MajesTEC-9 (2023) – A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 prior lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide – Principal Investigator
BELLWAVE (2024) – A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Ibrutinib or Acalabrutinib) in Participants with Untreated Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma – Principal Investigator
GOLSEEK (2025) – A phase 3, Multicenter, Randomized, Double Blind, Placebo- controlled Study. Comparing the Efficacy and Safety of Golcadomide plus R-CHOP Chemotherapy vs Placebo plus RCHOP Chemotherapy in Participants with Previously Untreated High – risk Large B cell Lymphoma – Principal Investigator

Publikasi

Variable CD34+ recovery of cryopreserved allogenic HPC products: transplant implication during the COVID -19 pandemic – Co-author and Site Investigator, Blood advance: published 4/9/2021.
Genotype and Clinical Characterisation of HbH disease in Malaysian Patients – First author, British Journal of Hematology: published 3/4/2022.
Risk factors and outcome of COVID-19 infection in Hematological Patients: A Multicenter Retrospective Analysis in Malaysia, First author, Blood (2022) 140 (Supplement 1): 13232-13233
A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy in Heavily Pretreated Chronic GVHD Patients with Steroid Failure – Co-author and Site Investigator, Transplantation and Cellular Therapy (2022) 1-9
Utility of Osteoporosis Medications in Palliative Care and Oncology – co-author, pharmacological interventions for Osteoporosis (pp.103-118)

Bahasa